0000000000281587

AUTHOR

Kai-uwe Eckardt

showing 3 related works from this author

Positive Iron Balance in Chronic Kidney Disease: How Much is Too Much and How to Tell?

2017

<b><i>Background:</i></b> Regulation of body iron occurs at cellular, tissue, and systemic levels. In healthy individuals, iron absorption and losses are minimal, creating a virtually closed system. In the setting of chronic kidney disease and hemodialysis (HD), increased iron losses, reduced iron absorption, and limited iron availability lead to iron deficiency. Intravenous (IV) iron therapy is frequently prescribed to replace lost iron, but determining an individual’s iron balance and stores can be challenging and imprecise, contributing to uncertainty about the long-term safety of IV iron therapy. <b><i>Summary:</i></b> Patients on HD recei…

Iron030232 urology & nephrologyPhysiology030204 cardiovascular system & hematologyDirect reduced iron03 medical and health sciences0302 clinical medicineHepcidinmedicineHomeostasisHumansErythropoiesisRenal Insufficiency ChronicHemochromatosischemistry.chemical_classificationbiologybusiness.industryIron deficiencymedicine.diseaseTrace ElementschemistryNephrologyTransferrinToxicitybiology.proteinErythropoiesisAdministration IntravenousbusinessKidney diseaseAmerican journal of nephrology
researchProduct

Kinetics of Renal Function during Induction in Newly Diagnosed Multiple Myeloma: Results of Two Prospective Studies by the German Myeloma Study Group…

2021

Background: Preservation of kidney function in newly diagnosed (ND) multiple myeloma (MM) helps to prevent excess toxicity. Patients (pts) from two prospective trials were analyzed, provided postinduction (PInd) restaging was performed. Pts received three cycles with bortezomib (btz), cyclophosphamide, and dexamethasone (dex

renal failurekidneyendocrine systemCancer Researchmedicine.medical_specialtyCyclophosphamide030232 urology & nephrologyUrologyRenal functionlcsh:RC254-282NiereninsuffizienzArticleBortezomib03 medical and health sciences0302 clinical medicineMultiple myelomamedicineddc:610Renal insufficiencyLenalidomideDexamethasoneMultiple myelomaLenalidomideKidneybusiness.industryBortezomiblcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensinduction regimenmedicine.disease3. Good healthmedicine.anatomical_structureOncology030220 oncology & carcinogenesisPlasmozytombusinessDDC 610 / Medicine & healthKidney diseasemedicine.drugCancers
researchProduct

Blood pressure in chronic kidney disease stage 5D—report from a Kidney Disease: Improving Global Outcomes controversies conference

2010

Management of blood pressure (BP) in patients with chronic kidney disease receiving dialysis (stage 5D) provides a significant challenge for healthcare professionals. The association between BP and cardiovascular disease risk has been well studied in the general population; however, in dialysis patients, physiological and dialysis-related mechanisms influencing BP are complex, and the associated risk is poorly understood. In stage 5D, BP is determined by the complex interplay of fluid volume and prescription of post-dialysis target weight, sodium load, the renin–angiotensin and sympathetic nervous systems, and diverse exogenous factors, such as administration of erythropoiesis-stimulating a…

medicine.medical_specialtyhypotensionhypertensionmedicine.medical_treatmentPopulationLeft ventricular hypertrophylaw.inventionRandomized controlled triallawMedicineantihypertensiveMedical prescriptioneducationIntensive care medicinesodium managementDialysiseducation.field_of_studybusiness.industryGuidelinemedicine.diseaseBlood pressureNephrologydialysisbusinesschronic kidney diseaseKidney diseaseKidney International
researchProduct